Current Report Filing (8-k)
March 16 2017 - 4:41PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported):
March
16, 2017
BioTime,
Inc.
(Exact name of registrant as specified in its charter)
California
|
1-12830
|
94-3127919
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
1010 Atlantic Avenue
Suite 102
Alameda, California 94501
(Address
of principal executive offices)
(510)
521-3390
(Registrant's
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Forward-Looking Statements
Any statements that are not historical fact (including, but not
limited to statements that contain words such as “may,” “will,”
“believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”)
should also be considered to be forward-looking statements. Additional
factors that could cause actual results to differ materially from the
results anticipated in these forward-looking statements are contained in
BioTime’s periodic reports filed with the SEC under the heading “Risk
Factors” and other filings that BioTime may make with the Securities and
Exchange Commission. Undue reliance should not be placed on these
forward-looking statements which speak only as of the date they are
made, and the facts and assumptions underlying these statements may
change. Except as required by law, BioTime disclaims any intent or
obligation to update these forward-looking statements.
References in this Report to “BioTime,” “we” or “us” refer to
BioTime, Inc.
This Report and the accompanying Exhibit 99.1 shall be deemed
“furnished” and not “filed” under Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liability of that section, and shall not be incorporated by
reference into any filings made by BioTime under the Securities Act of
1933, as amended, or the Exchange Act except as may be expressly set
forth by specific reference in such filing.
Section 2 - Financial Information
Item 2.02 - Results of Operations and Financial Condition
On March 16, 2017, BioTime, Inc. issued a press release announcing its
financial results for the fourth quarter and fiscal year ended December
31, 2016. A copy of the press release is attached as Exhibit 99.1,
which, in its entirety, is incorporated herein by reference.
Section 9 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits.
Exhibit Number
|
|
Description
|
99.1
|
|
Press release dated March 16, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
BIOTIME, INC.
|
|
|
|
|
|
|
|
Date:
|
March
16, 2017
|
By:
|
|
/s/ Russell Skibsted
|
|
|
|
|
|
Chief Financial Officer
|
|
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024